Page 11 - Pharma

Drugmakers slash prices to be eligible for China's bulk-buy program

Sale prices of over 100 types of commonly used drugs are on average about 17 to 18 times of their manufacturing costs, the statement said

Ready with the innovation edge

Global capability centres will drive innovation for the global enterprise

Q3 results preview: US regulatory overhang on earnings of pharma firms

The US is Indian pharma's largest export market and Indian drugmakers account for a little over 30 per cent of generic drugs sold in that country

Gene therapy to conquering hepatitis C: A decade of medical breakthroughs

Putting aside prices for a moment, it's been an exciting period for medical progress

NITI Aayog plans to bring all medical devices under one regulatory regime

The NITI Aayog has proposed to do away with the need to have manufacturing licences to register a medical device

Pharma sector likely to grow at 10-12% during FY19-22, outlook stable: Icra

Icra cited abating headwinds from pricing pressure in the US, stable growth for the Indian market driven by increasing healthcare spending

Price hike, at last

Govt should not control drug prices

Ceiling prices of 21 key medicines raised by 50%; NPPA invokes DPCO 2013

The prices of APIs have gone up in the range of 5-88%

Stricter regulations, pricing control slow down pharma sector growth

The fifth part of the series looks at what's ailing the pharma sector

Aurobindo recalls heartburn drug ranitidine, two others from US market

Development follows regulatory compliance issues being faced by several of its plants back home; Ranitidine taken off due to the presence of carcinogenic compound

Dr Reddy's launches cancer treatment drug Bortezomib in the US market

Bortezomib is an active ingredient similar to that of the once blockbuster cancer treatment Velcade of Millennium Pharmaceuticals

MedLife's secret sauce behind delivering medicines in less than 2 hours

MedLife has mobile apps for everyone, and a smartphone is where all the tasks happen

Indian pharma cos with bigger US presence face more FDA scrutiny: Analysts

Big entities such as Aurobindo and Dr Reddy's have been currently filing for new product approvals from multiple sites

Develop entire value chain: Dr Reddy's MD tells pharma companies

US-China trade war is going to give us a window of opportunity to expand our industry, says G V Prasad

GPAT 2020 registration process begins: Know important dates, steps to apply

GPAT is a national-level entrance examination for admission to MPharma programmes

Pharma Q2 Preview: Lack of new US approvals to overshadow domestic revival

Analysts expect a 12% growth in revenues for the sector

Pharma Monday blues: USFDA warnings drag down Glenmark, Aurobindo stocks

The Nifty Pharma index fell 3.35 per cent during the day.

Pharma PSUs likely to sign MoU with LMA for sale of surplus land

The PSUs thus are hopeful that the sale process could now be expedited

We are growing our biosimilars capacity six-fold: Lupin MD Nilesh D Gupta

We were into APIs in the US and we started finished products, said Nilesh D Gupta

Pfizer clears the decks for fresh start, looks to energise bestseller list

With six big brands that never hit the high notes in India, bundled into its venture with Mylan, the pharma major looks to energise its bestseller list